Terms: = Kidney tumors AND BRCA2, FAD, 675, ENSG00000139618, FACD, FAD1, FANCD, FANCD1, BRCC2, RP11-298P3_4
23442 results:
1. Modeling Physical Forces Experienced by Cancer and Stromal Cells Within Different Organ-Specific Tumor Tissue.
Connaughton M; Dabagh M
IEEE J Transl Eng Health Med; 2024; 12():413-434. PubMed ID: 38765886
[TBL] [Abstract] [Full Text] [Related]
2. Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib.
Lin Z; Xiao S; Qi Y; Guo J; Lu L
J Cancer Res Clin Oncol; 2024 May; 150(5):262. PubMed ID: 38762825
[TBL] [Abstract] [Full Text] [Related]
3. Contrast-enhanced ultrasound for differentiating benign from malignant focal solid renal lesions in pediatric patients.
Fu Y; Zhong J; Tan Y; Zheng T; Liu M; Wang G
Sci Rep; 2024 May; 14(1):11409. PubMed ID: 38762673
[TBL] [Abstract] [Full Text] [Related]
4. Association between metabolic syndrome and kidney cancer risk: a prospective cohort study.
Wang L; Du H; Sheng C; Dai H; Chen K
Lipids Health Dis; 2024 May; 23(1):142. PubMed ID: 38760801
[TBL] [Abstract] [Full Text] [Related]
5. Development and validation of a nomogram for predicting the occurrence of renal dysfunction after treatment of immune checkpoint inhibitor: a retrospective case-control study.
Su J; Chen P; Yang Y; Gao Z; Bi Z; Feng M
BMJ Open; 2024 May; 14(5):e082484. PubMed ID: 38760047
[TBL] [Abstract] [Full Text] [Related]
6. Evaluating the effects of various ethanolic medicinal plant extracts on metastatic breast cancer proliferation, invasion, and expression of a novel potential drug target; CD82 metastatic suppressor protein, and on in vivo angiogenesis using the ex ovo yolk sac membrane (YSM) assay.
Loggenberg S; Twilley D; Lall N
J Cancer Res Clin Oncol; 2024 May; 150(5):257. PubMed ID: 38753184
[TBL] [Abstract] [Full Text] [Related]
7. Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.
Kurmasheva N; Said A; Wong B; Kinderman P; Han X; Rahimic AHF; Kress A; Carter-Timofte ME; Holm E; van der Horst D; Kollmann CF; Liu Z; Wang C; Hoang HD; Kovalenko E; Chrysopoulou M; Twayana KS; Ottosen RN; Svenningsen EB; Begnini F; Kiib AE; Kromm FEH; Weiss HJ; Di Carlo D; Muscolini M; Higgins M; van der Heijden M; Bardoul A; Tong T; Ozsvar A; Hou WH; Schack VR; Holm CK; Zheng Y; Ruzek M; Kalucka J; de la Vega L; Elgaher WAM; Korshoej AR; Lin R; Hiscott J; Poulsen TB; O'Neill LA; Roy DG; Rinschen MM; van Montfoort N; Diallo JS; Farin HF; Alain T; Olagnier D
Nat Commun; 2024 May; 15(1):4096. PubMed ID: 38750019
[TBL] [Abstract] [Full Text] [Related]
8. End-stage renal disease after renal cancer surgery: risk factors and overall survival.
Åkerlund J; Ljungberg B; Lundstam S; Peeker R; Holmberg E; Månsson M; Grenabo Bergdahl A
Scand J Urol; 2024 May; 59():109-116. PubMed ID: 38747153
[TBL] [Abstract] [Full Text] [Related]
9. Deep Learning Assessment of Small Renal Masses at Contrast-enhanced Multiphase CT.
Dai C; Xiong Y; Zhu P; Yao L; Lin J; Yao J; Zhang X; Huang R; Wang R; Hou J; Wang K; Shi Z; Chen F; Guo J; Zeng M; Zhou J; Wang S
Radiology; 2024 May; 311(2):e232178. PubMed ID: 38742970
[TBL] [Abstract] [Full Text] [Related]
10. Minimally invasive transperitoneal partial versus radical nephrectomy in obese patients: perioperative and long-term functional outcomes from a large perspective contemporary series (RECORd2 project).
Lambertini L; Mari A; Sandulli A; Amparore D; Antonelli A; Barale M; Bove P; Brunocilla E; Capitanio U; DA Pozzo LF; DI Maida F; Grosso AA; Fiori C; Gontero P; Li Marzi V; Campi R; Longo N; Marchioni M; Montanari E; Montorsi F; Porpiglia F; Porreca A; Schiavina R; Simeone C; Siracusano S; Terrone C; Ficarra V; Minervini A
Minerva Urol Nephrol; 2024 Apr; 76(2):185-194. PubMed ID: 38742553
[TBL] [Abstract] [Full Text] [Related]
11. Single-layer versus double-layer renorrhaphy technique during robot-assisted partial nephrectomy: impact on perioperative outcomes, complications, and functional outcomes.
Bertolo R; Ditonno F; Veccia A; DE Marco V; Migliorini F; Porcaro AB; Rizzetto R; Cerruto MA; Autorino R; Antonelli A
Minerva Urol Nephrol; 2024 Apr; 76(2):176-184. PubMed ID: 38742552
[TBL] [Abstract] [Full Text] [Related]
12. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
[TBL] [Abstract] [Full Text] [Related]
13. Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma.
Sammarco E; Rossetti M; Salfi A; Bonato A; Viacava P; Masi G; Galli L; Faviana P
Med Oncol; 2024 May; 41(6):150. PubMed ID: 38740647
[TBL] [Abstract] [Full Text] [Related]
14. Surface ligand-regulated renal clearance of MRI/SPECT dual-modality nanoprobes for tumor imaging.
Chen C; Huang B; Zhang R; Sun C; Chen L; Ge J; Zhou D; Li Y; Wu S; Qian Z; Zeng J; Gao M
J Nanobiotechnology; 2024 May; 22(1):245. PubMed ID: 38735921
[TBL] [Abstract] [Full Text] [Related]
15. Comparison of Perioperative, Functional, and Oncologic Outcomes of Open vs. Robot-Assisted Off-Clamp Partial Nephrectomy: A Propensity Scored Match Analysis.
Mastroianni R; Chiacchio G; Perpepaj L; Tuderti G; Brassetti A; Anceschi U; Ferriero M; Misuraca L; D'Annunzio S; Bove AM; Guaglianone S; Flammia RS; Proietti F; Pula M; Milanese G; Leonardo C; Galosi AB; Simone G
Sensors (Basel); 2024 Apr; 24(9):. PubMed ID: 38732928
[TBL] [Abstract] [Full Text] [Related]
16. Comparison of dmft and behavior rating scores between children with systemic disease and healthy children at the first dental visit.
Erbas Unverdi G; Ozgur B; Gungor HC; Casamassimo PS
BMC Oral Health; 2024 May; 24(1):548. PubMed ID: 38730438
[TBL] [Abstract] [Full Text] [Related]
17. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review.
Turjap M; Pelcová M; Gregorová J; Šmak P; Martin H; Štingl J; Peš O; Juřica J
Ther Drug Monit; 2024 Jun; 46(3):321-331. PubMed ID: 38723115
[TBL] [Abstract] [Full Text] [Related]
18. Comparing Sonazoid contrast-enhanced ultrasound to contrast-enhanced CT and MRI for differentially diagnosing renal lesions: a prospective multicenter study.
Zhao QX; Wu C; Tan S; Yang Y; Cui XW; Dietrich CF; Yang B; Xu CL; Gao YY; Xie MX; Wu CJ; Liu LP; Wang XH; Ling-Hu RZ; Wang N; Wang F; Wang XL; Liu GY; Yu XL; Yu J; Cheng ZG; Liang P
World J Urol; 2024 May; 42(1):302. PubMed ID: 38720010
[TBL] [Abstract] [Full Text] [Related]
19. Risk of Subsequent Primary Cancers Among Adult-Onset 5-Year Cancer Survivors in South Korea: Retrospective Cohort Study.
Choi YY; Lee M; Kim EH; Lee JE; Jung I; Cheong JH
JMIR Public Health Surveill; 2024 May; 10():e48380. PubMed ID: 38717807
[TBL] [Abstract] [Full Text] [Related]
20. Clinical and pathological characteristics of renal cell carcinomas with MiTF translocation.
Filler T; Verkarre V; Peyrottes A; Poinard F; Lupo A; Dariane C; Hurel S; Timsit MO; Mejean A; Audenet F
Fr J Urol; 2024 Mar; 34(2):102569. PubMed ID: 38717457
[TBL] [Abstract] [Full Text] [Related]
[Next]